Adaptimmune Therapeutics PLC
Adaptimmune is working to redefine the treatment of challenging solid tumor cancers. They utilize a proprietary cell therapy platform, engineering a patient's own cells to fight cancer, with the goal of significantly improving the patient's treatment experience across a variety of solid tumor cancers. Adaptimmune is a fully integrated company with capabilities in research, clinical development, commercialization, and manufacturing.
Registre Officiel
Dernière vérification: 1/2/2026
Analyse Qualité IA
Détails du Score de Confiance
Liens Rapides
Points forts du site
🌟 Entreprises similaires de confiance
Context Therapeutics Inc.
Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.
AGENUS INC
Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.
Sigyn Therapeutics, Inc.
Sigyn Therapeutics develops dialysis-like therapies for cardiovascular disease and cancer. Their therapies are designed to improve patient quality of life. Key products include CardioDialysis™ for cardiovascular disease, and ImmunePrep™, ChemoPrep™ and ChemoPure™ for cancer therapy.